Dragonfly will use its TriNKET™ platform to develop drug
candidates directed to multiple targets for autoimmune
disorders, and oncology. AbbVie receives exclusive
options to license a number of Dragonfly's natural killer
(NK) cell engager immunotherapies.
WALTHAM, Mass., Nov. 20, 2019 /PRNewswire/ -- Dragonfly
Therapeutics ("Dragonfly"), a biotechnology company developing
novel immunotherapies that harness the innate immune system to
treat disease, and AbbVie (NYSE: ABBV), a research-based global
biopharmaceutical company, today announced a multi-target research
collaboration designed to advance a number of Dragonfly's novel NK
cell engager-based immunotherapies for autoimmune and oncology
indications.
The collaboration grants AbbVie the option to license exclusive
worldwide intellectual property rights to develop and commercialize
products directed to specific targets developed using Dragonfly's
TriNKET™ technology platform.
"AbbVie is committed to delivering improved treatment options to
our patients by investing in groundbreaking technologies and
platforms," said Tom Hudson, M.D.
Senior Vice President, R&D and Chief Scientific Officer at
AbbVie. "The Dragonfly team has made impressive progress in
developing their platform and demonstrating the potential of their
technology to potentially treat a variety of diseases."
"AbbVie is a global leader in treating chronic immune-mediated
diseases, and transforming standards of care for people living with
cancer," said Bill Haney, co-founder
and chief executive officer of Dragonfly. "We look forward to
working with the AbbVie team to advancing new treatment options for
patients."
AbbVie will pay Dragonfly an upfront payment, future
success-based milestone payments and royalties.
About Dragonfly
Dragonfly Therapeutics is a
clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing therapies that use its novel
TriNKET™ technology to harness the body's innate immune system to
bring breakthrough cancer treatments to patients.
For more information visit:
www.dragonflytx.com
https://www.linkedin.com/company/dragonfly-therapeutics-inc.
https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT:
Anne Deconinck |
anne@dragonflytx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-collaboration-with-abbvie-for-autoimmune-diseases-and-oncology-300961954.html
SOURCE Dragonfly Therapeutics, Inc.